Bioniche Granted Patent for Oligonucleotide Technology
News Mar 17, 2006
Bioniche Life Sciences Inc. has announced that it has been granted a European patent - EP1432450 - covering the composition and use of an oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides", inventors Dr. Nigel C. Phillips, Dr. Mario C. Filion, and Dr. Andrea Herrera-Gayol.
Dr. Nigel C. Phillips, Chief Scientific Officer for Bioniche Life Sciences Inc. stated, "This patent consolidates our oligonucleotide patent portfolio. These oligonucleotides constitute a new composition family that enhances our ability to develop effective treatments for oncology indications."
"Bioniche now has technology platforms based on mycobacterial cell walls, unmodified oligonucleotides and modified oligonucleotides that have immune stimulant and anticancer activity."
"Bioniche is in a position to develop effective treatments for cancer using these unique and complementary technology platforms."
Graeme McRae, President & CEO of Bioniche Life Sciences Inc., commented, "The oligonucleotide platform is another example of Bioniche's ability to develop novel technologies."
"We plan to develop this platform through additional pre-clinical research in the immunomodulatory and anti-cancer areas and seek opportunities to partner the technology for further development."
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.